AG真人官方

Entrada Therapeutics (TRDA) 鈥� Form 4 insider transaction summary

Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).

• 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
• 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
• The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.

No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.

Form 4 filings dated 07/01/2025 disclose that venture鈥揵acked funds affiliated with 5AM Venture Management, a 10 % beneficial owner of Entrada Therapeutics (TRDA), executed a three-day program of open-market sales. The entities involved were 5AM Ventures V, L.P. (direct holder) and 5AM Opportunities I, L.P. (indirect holder). The sales were made on 06/27, 06/30 and 07/01 at prices ranging from $6.81 鈥� $7.12 per share.

• Shares sold by 5AM Ventures V: 92,891 shares (55,735 + 18,578 + 18,578) for proceeds of roughly $639k.
• Shares sold by 5AM Opportunities I: 32,109 shares (19,265 + 6,422 + 6,422) for proceeds of roughly $220k.
• Total shares sold: 125,000 shares, representing about 2.8 % of the combined 4.41 million-share position held prior to the first transaction.

After the transactions, 5AM Ventures V holds 3,183,131 shares directly, while 5AM Opportunities I holds 1,100,248 shares indirectly, leaving the 5AM group with an aggregate stake of approximately 4.28 million shares. All reporting persons鈥�5AM Partners V, 5AM Opportunities I (GP), and managing members Dr. Scott M. Rocklage and Andrew J. Schwab鈥攔emain classified as 10 % owners. No derivative securities were reported.

The filing signals modest insider selling by a large shareholder following a minor upward move in TRDA鈥檚 share price during the period. Although the group maintains a substantial ownership position, the reduction could be interpreted by investors as a slight negative sentiment shift or portfolio rebalancing.

Entrada Therapeutics, Inc. (TRDA) 鈥� Form 144 filing

An affiliate has filed a Form 144 to sell up to 19,265 common shares through TD Securities (USA) LLC on or after 27 June 2025. The proposed transaction carries an aggregate market value of $133,121.15. The shares were originally acquired on 28 September 2017 via a cash venture investment. With 37,953,417 shares outstanding, the maximum sale equals roughly 0.05 % of the issuer鈥檚 float, indicating minimal dilution or price pressure.

No other sales have been reported in the past three months, and the filer states they possess no undisclosed material adverse information. Form 144 is a notice only; it does not obligate the seller to complete the trade and provides no operating or earnings data. Given the small size of the stake, the market impact is expected to be immaterial, though investors often interpret insider intentions to sell as a mildly negative sentiment indicator.

Entrada Therapeutics, Inc. (NASDAQ: TRDA) 鈥� Form 144 filing dated 06/27/2025

The notice discloses that 5AM Ventures V, L.P., an affiliate of director Andrew J. Schwab, intends to sell up to 55,735 common shares of Entrada Therapeutics through TD Securities (USA) LLC on or about 06/27/2025. The shares to be sold represent roughly 0.15 % of the company鈥檚 37,953,417 shares outstanding. The aggregate market value of the planned sale, based on the Form 144 calculation, is $385,128.85.

The securities were originally acquired on 09/28/2017 as a cash-funded venture investment. No other sales by the same party have occurred during the past three months, and the filer affirms that it possesses no undisclosed material adverse information regarding Entrada鈥檚 operations. The filing is marked 鈥淟IVE,鈥� indicating an actual proposed disposition under SEC Rule 144, which permits resale of restricted securities if volume and timing conditions are met.

Investors typically monitor Form 144 filings because they may signal insider intentions to reduce holdings; however, the volume disclosed here is modest relative to Entrada鈥檚 float and does not, by itself, alter control dynamics. The declaration of no undisclosed adverse information and the use of a registered broker suggest the transaction is routine and compliant with securities regulations.

On 06/18/2025, Entrada Therapeutics (TRDA) filed a Form 4/A amending its prior insider-trading report. The filing discloses that director Peter S. Kim bought an additional 25,000 common shares on 05/13/2024 at a weighted-average price of $14.6804. This transaction was omitted from the original Form 4 filed on 05/16/2024, which had already reported a separate 25,000-share purchase on 05/14/2024 at $14.5869.

After including both purchases, Kim now directly owns 117,412 TRDA shares. No derivative securities were reported. The amendment corrects share totals and indicates that the director accumulated 50,000 shares over two consecutive trading days, a potential sign of insider confidence despite the minor reporting lapse.